Absorb® bioresorbable scaffold in “established” versus “off-label” coronary lesions: 5-year data from the GABI-R® registry
Clinical Research in Cardiology · 2025
DOI: 10.1007/s00392-025-02707-3 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Clinical Research in Cardiology, 2025. Verfasst von Aydin Huseynov und 16 weiteren Autor:innen. Beteiligte Einrichtung: First Department of Medicine-Cardiology, Faculty of Medicine Mannheim, University Medical Centre Mannheim, University of Heidelberg, Theodor-Kutzer-U…. Hauptthemen laut MEDLINE: Absorbable Implants, Coronary Artery Disease, Drug-Eluting Stents, Off-Label Use. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Abbott Vascular, Medizinische Fakultät Mannheim der Universität Heidelberg.
Abstract (Originalsprache)
Background
The potential benefits of bioabsorbable stents can be better assessed over the long term. The implantation of bioresorbable scaffold (BRS) in situations with off-label indications provides real-world insights into how clinical events differ in contrast to standard proved indications.
Objectives
The study provides long-term follow-up data about the use of bioresorbable scaffold (BRS) for off-label compared with approved indications.
Methods
Five-year outcome data of an everolimus-eluting, poly-L-lactic acid–based bioresorbable scaffold system (ABSORB, Abbott Vascular, Santa Clara, CA, USA) were evaluated in the prospective, non-interventional, multicenter real-world German-Austrian ABSORB-RegIstRy (GABI-R). The patients were enrolled from a total of 93 centers. Data processing and prospective follow-up were conducted centrally and independently of industry.
Results
A total of 3082 patients were enrolled between 2013 and 2016. Most patients were included into the off-label group (2317, 75.2%). ST-elevation myocardial infarction (STEMI) was significantly more common in the off-label group (35.9% vs. 27.8%, p = 0.003), and the extent of coronary heart disease was higher in the off-label group (coronary 3 vessel disease 28.4% vs. 22.4%, p < 0.001). Patients with off-label indications had statistically significant higher rates of stent thrombosis after 30 days (1.08% vs. 0.26%, p = 0.04) and target vessel failure (TVF) after 6 months (4.62% vs. 2.61%, p = 0.02).
Conclusions
The off-label use of BRS is associated with a higher rate of stent thrombosis in the short term and in the long term with higher MACE events considering more complex lesions and a higher morbidity. In the long term, there are no differences regarding stent thrombosis. Graphical Abstract
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- First Department of Medicine-Cardiology, Faculty of Medicine Mannheim, University Medical Centre Mannheim, University of Heidelberg, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany. a.n.huseynov@gmail.com.
- DZHK (German Centre for Cardiovascular Research), Partner Site Heidelberg/Mannheim, Mannheim, Germany. a.n.huseynov@gmail.com.
- First Department of Medicine-Cardiology, Faculty of Medicine Mannheim, University Medical Centre Mannheim, University of Heidelberg, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany.
- DZHK (German Centre for Cardiovascular Research), Partner Site Heidelberg/Mannheim, Mannheim, Germany.
- Heart Centre Segebereger Kliniken GmbH, Bad Segeberg, Germany.
- Department of Cardiology, University of Giessen, Giessen, Germany.
Förderung
- Abbott Vascular
- Medizinische Fakultät Mannheim der Universität Heidelberg
Zitieren
APA
Huseynov, A., Behnes, M., Nef, H., Riemer, T., Schneider, S., Pfannebecker, T., Achenbach, S., Mehilli, J., Münzel, T., Gori, T., Wöhrle, J., Zahn, R., Kastner, J., Schmermund, A., Richardt, G., Hamm, C. W., & Akin, I. (2025). Absorb® bioresorbable scaffold in “established” versus “off-label” coronary lesions: 5-year data from the GABI-R® registry. Clinical Research in Cardiology. https://doi.org/10.1007/s00392-025-02707-3
Vancouver
Huseynov A, Behnes M, Nef H, Riemer T, Schneider S, Pfannebecker T, et al. Absorb® bioresorbable scaffold in “established” versus “off-label” coronary lesions: 5-year data from the GABI-R® registry. Clinical Research in Cardiology. 2025. doi:10.1007/s00392-025-02707-3
BibTeX
@article{Huseynov2025,
author = {Huseynov, Aydin and Behnes, Michael and Nef, Holger and Riemer, Thomas and Schneider, Steffen and Pfannebecker, Thomas and Achenbach, Stephan and Mehilli, Julinda and Münzel, Thomas and Gori, Tommaso and Wöhrle, Jochen and Zahn, Ralf and Kastner, Johannes and Schmermund, Axel and Richardt, Gert and Hamm, Christian W and Akin, Ibrahim},
title = {Absorb® bioresorbable scaffold in “established” versus “off-label” coronary lesions: 5-year data from the GABI-R® registry},
journal = {Clinical Research in Cardiology},
year = {2025},
doi = {10.1007/s00392-025-02707-3}
}
EUVIMED